CVS / CVS Health Corporation - SEC-Einreichungen, Jahresbericht, Proxy Statement

May 22, 2026

EX-15.1 Exhibit 15.1 May 22, 2026 To the Shareholders and the Board of Directors of CVS Health Corporation We are aware of the incorporation by reference in this Registration Statement (Form S-3) of CVS Health Corporation for the offering of debt securities of our report dated May 6, 2026 relating to the unaudited condensed consolidated interim financial statements of CVS Health Corporation that i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE

EX-25.1 Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A. (Exact name of trustee as specified in its char

As filed with the Securities and Exchange Commission on May 22, 2026

S-3ASR Table of Contents As filed with the Securities and Exchange Commission on May 22, 2026 Registration No.

As filed with the Securities and Exchange Commission on May 22, 2026

S-8 As filed with the Securities and Exchange Commission on May 22, 2026 Registration No.

May 22, 2026

EX-15 Exhibit 15 May 22, 2026 To the Shareholders and the Board of Directors of CVS Health Corporation We are aware of the incorporation by reference in this Registration Statement (Form S-8) of CVS Health Corporation for the offering of common shares of our report dated May 6, 2026 relating to the unaudited condensed consolidated interim financial statements of CVS Health Corporation that is included in its Form 10-Q for the quarter ended March 31, 2026.

Security Type

Calculation of Filing Fee Tables S-3 CVS HEALTH Corp Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Debt Debt Securities 457(r) 0 $ 0.

Table 1: Newly Registered Securities

Calculation of Filing Fee Tables S-8 CVS HEALTH Corp Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE

EX-25.2 Exhibit 25.2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A. (Exact name of trustee as specified in its char

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2026 (May 14, 2026) CVS H

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2026 (May 14, 2026) CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation)

CVS HEALTH CORPORATION NONQUALIFIED STOCK OPTION AGREEMENT GRANT DATE: %%OPTION_DATE,'Month DD, YYYY'%-%

Exhibit 10.7 CVS HEALTH CORPORATION NONQUALIFIED STOCK OPTION AGREEMENT GRANT DATE: %%OPTIONDATE,'Month DD, YYYY'%-% 1.GRANT OF AWARD. Pursuant and subject to the provisions of the 2017 Incentive Compensation Plan of CVS Health Corporation (the “Plan”), on the date set forth above (the “Grant Date”), CVS Health Corporation (the “Company”) has granted and hereby evidences the award to the person na

CVS HEALTH CORPORATION

Exhibit 10.4 CVS HEALTH CORPORATION Change in Control Agreement for Brian Newman Confidential Revised 2020 Page 1. Definitions 1 2. Term of Agreement 4 3. Entitlement to Severance Benefit 5 4. Confidentiality; Cooperation with Regard to Litigation; Non-disparagement 7 5. Non-solicitation 8 6. Remedies 8 7. Effect of Agreement on Other Benefits 9 8. Not an Employment Agreement 9 9. Resolution of Di

CVS HEALTH CORPORATION PERFORMANCE STOCK UNIT AGREEMENT GRANT DATE: %%OPTION_DATE,'Month DD, YYYY'%-%

Exhibit 10.9 CVS HEALTH CORPORATION PERFORMANCE STOCK UNIT AGREEMENT GRANT DATE: %%OPTIONDATE,'Month DD, YYYY'%-% 1. GRANT OF AWARD. Pursuant and subject to the provisions of the 2017 Incentive Compensation Plan of CVS Health Corporation (the “Plan”), on the date set forth above (the “Grant Date”), CVS Health Corporation (the “Company”) has granted and hereby evidences by the Performance Stock Uni

CVS Pharmacy, Inc. Restrictive Covenant Agreement

Exhibit 10.1 CVS Pharmacy, Inc. Restrictive Covenant Agreement Participant: Steven H. Nelson Employee ID: N/A I, Steven H. Nelson enter into this Restrictive Covenant Agreement (“Agreement”) with CVS Pharmacy, Inc., on its own behalf and on behalf of its subsidiaries and affiliates (“CVS”), which is effective as of the date I sign the Agreement (“Effective Date”). 1.Consideration for Agreement. In

CVS HEALTH CORPORATION RESTRICTED STOCK UNIT AGREEMENT GRANT DATE: %%OPTION_DATE,'Month DD, YYYY'%-%

Exhibit 10.6 CVS HEALTH CORPORATION RESTRICTED STOCK UNIT AGREEMENT GRANT DATE: %%OPTIONDATE,'Month DD, YYYY'%-% 1.GRANT OF AWARD. Pursuant and subject to the provisions of the 2017 Incentive Compensation Plan of CVS Health Corporation (the “Plan”), on the date set forth above (the “Grant Date”), CVS Health Corporation (the “Company”) has granted, and hereby evidences by the Restricted Stock Units

CVS HEALTH CORPORATION

Exhibit 10.2 CVS HEALTH CORPORATION Change in Control Agreement for Steven Nelson Confidential Revised 2020 Page 1. Definitions 1 2. Term of Agreement 4 3. Entitlement to Severance Benefit 5 4. Confidentiality; Cooperation with Regard to Litigation; Non-disparagement 7 5. Non-solicitation 8 6. Remedies 8 7. Effect of Agreement on Other Benefits 9 8. Not an Employment Agreement 9 9. Resolution of D

CVS Pharmacy, Inc. Restrictive Covenant Agreement

Exhibit 10.3 CVS Pharmacy, Inc. Restrictive Covenant Agreement Participant: Brian Newman Employee ID: I, Brian Newman enter into this Restrictive Covenant Agreement (“Agreement”) with CVS Pharmacy, Inc., on its own behalf and on behalf of its subsidiaries and affiliates (“CVS”), which is effective as of the date I sign the Agreement (“Effective Date”). 1.Consideration for Agreement. In connection

CVS HEALTH CORPORATION REPORTS STRONG FIRST QUARTER 2026 RESULTS AND RAISES FULL-YEAR 2026 GUIDANCE

Exhibit 99.1 CVS HEALTH CORPORATION REPORTS STRONG FIRST QUARTER 2026 RESULTS AND RAISES FULL-YEAR 2026 GUIDANCE •First quarter total revenues increased to $100.4 billion, up 6.2% year-over-year •First quarter GAAP diluted EPS of $2.30 and Adjusted EPS of $2.57 •Raising full-year 2026 guidance: ◦GAAP diluted EPS guidance range to $6.24 to $6.44 from $5.94 to $6.14 ◦Adjusted EPS guidance range to $

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-01011 CVS HEALT

CVS HEALTH SEVERANCE PLAN FOR NON-STORE EMPLOYEES (Amended and Restated as of March 15, 2026)

Exhibit 10.5 CVS HEALTH SEVERANCE PLAN FOR NON-STORE EMPLOYEES (Amended and Restated as of March 15, 2026) 1 Proprietary CVS HEALTH SEVERANCE PLAN FOR NON-STORE EMPLOYEES (Amended and Restated as of March 15, 2026) WHEREAS, CVS Health Corporation (the “Company”) has established the CVS Health Severance Plan for Non-Store Employees (the “Plan”) to provide financial assistance to employees in non-st

CVS HEALTH CORPORATION NONQUALIFIED STOCK OPTION AGREEMENT GRANT DATE: %%OPTION_DATE,'Month DD, YYYY'%-%

Exhibit 10.8 CVS HEALTH CORPORATION NONQUALIFIED STOCK OPTION AGREEMENT GRANT DATE: %%OPTIONDATE,'Month DD, YYYY'%-% 1.GRANT OF AWARD. Pursuant and subject to the provisions of the 2017 Incentive Compensation Plan of CVS Health Corporation (the “Plan”), on the date set forth above (the “Grant Date”), CVS Health Corporation (the “Company”) has granted and hereby evidences the award to the person na

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2026 CVS HEALTH CORPORATIO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2026 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation) (Commission File

Letter re: Unaudited Interim Financial Information

Exhibit 15.1 Letter re: Unaudited Interim Financial Information May 6, 2026 To the Shareholders and the Board of Directors of CVS Health Corporation We are aware of the incorporation by reference in the Registration Statements (Form S-3ASR No. 333-272200 and Form S-8 Nos. 333-279641, 333-273611, 333-271582, 333-270936, 333-238507, 333-230035, 333-228622, 333-167746, 333-217853, 333-208805, 333-141

Message from Our Chair of the Board and Our Lead Independent Director Notice of Annual Meeting of Stockholders Year-End 2025 Overview Proxy Statement Highlights Corporate Governance and Related Matters Audit Committee Matters Executive Compensation a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

ANNUAL REPORT TO SECURITY HOLDERS

Reimagining health care. Simplifying experiences. Earning trust. 2025 Annual Report Simplifying experiences. Earning trust. 2025 Annual Report To my fellow stockholders: Our heaLth touches every part of our lives. It's deeply personaL — shaped by our circumstances, our communities and the peopLe we love. It's foundational and arguably the most important asset we have — because without our heaLth,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )

CVS HEALTH CORPORATION DEFA 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

DEFINITIVE PROXY STATEMENT

Notice of Annual Meeting of Stockholders and Proxy Statement May 14, 2026 | Virtual Meeting at 8:00 a.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2026 (March 18, 2026) C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2026 (March 18, 2026) CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporati

DESCRIPTION OF COMMON STOCK REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

Exhibit 4.41 DESCRIPTION OF COMMON STOCK REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description (this “Description”) of the terms of the common stock of CVS Health Corporation (“CVS Health”) is a summary only and is qualified by reference to the relevant provisions of Delaware law and the Restated Certificate of Incorporation (the “Charter”) and the By-Laws (t

CVS HEALTH CORPORATION PROMOTION GRANT PREMIUM PRICED NQSO/SAR AWARD AGREEMENT GRANT DATE: November 30, 2024

Exhibit 10.68 CVS HEALTH CORPORATION PROMOTION GRANT PREMIUM PRICED NQSO/SAR AWARD AGREEMENT GRANT DATE: November 30, 2024 1.GRANT OF AWARD. Pursuant and subject to the provisions of the 2017 Incentive Compensation Plan of CVS Health Corporation (the “Plan”), on the date set forth above (the “Grant Date”), CVS Health Corporation (the “Company”) has granted and hereby evidences the award to the per

Subsidiaries of CVS Health Corporation

Exhibit 21.1 Subsidiaries of CVS Health Corporation Listed below are subsidiaries under CVS Health Corporation at December 31, 2025 with their jurisdictions of organization shown in parentheses. Subsidiaries excluded from the list below are not insurance companies and would not, in the aggregate, constitute a “significant subsidiary” of CVS Health Corporation, as that term is defined in Rule 1-02(

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2026 CVS HEALTH CORP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2026 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation) (Commissio

CVS HEALTH CORPORATION REPORTS FOURTH QUARTER AND FULL-YEAR 2025 RESULTS

Exhibit 99.1 CVS HEALTH CORPORATION REPORTS FOURTH QUARTER AND FULL-YEAR 2025 RESULTS Fourth Quarter Highlights •Total revenues increased to $105.7 billion, up 8.2% compared to prior year •GAAP diluted EPS of $2.30 and Adjusted EPS of $1.09 Full-Year Highlights •Total revenues increased to a record high $402.1 billion, up 7.8% compared to prior year •GAAP diluted EPS of $1.39 and Adjusted EPS of $

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-01011 CVS HEALTH COR

CVS Health Updates Financial Guidance, Highlights Strength of Businesses, and Announces Strategy to Uniquely Reimagine Health Care at Investor Day Event

Exhibit 99.1 CVS Health Updates Financial Guidance, Highlights Strength of Businesses, and Announces Strategy to Uniquely Reimagine Health Care at Investor Day Event •Outlines strategy to deliver best-in-class execution, transform consumer experiences, be the partner of choice, and harness unique enterprise capabilities •Updates 2025 full-year financial guidance; provides 2026 full-year financial

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2025 CVS HEALTH CORPO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2025 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 20, 2025 CVS HEALTH CORPOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 20, 2025 CVS HEALTH CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-01011 05-0494040 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

WOONSOCKET, RI (November 20, 2025) – CVS Health (NYSE: CVS) today announced that its Board of Directors has elected President and Chief Executive Officer David Joyner as its Chair of the Board, effective January 1, 2026. Following the effective date

EX-99.1 Exhibit 99.1 PRESS RELEASE WOONSOCKET, RI (November 20, 2025) – CVS Health (NYSE: CVS) today announced that its Board of Directors has elected President and Chief Executive Officer David Joyner as its Chair of the Board, effective January 1, 2026. Following the effective date of this appointment, Michael Mahoney will continue to serve as the Board’s Lead Independent Director, and Roger Far

CVS HEALTH CORPORATION REPORTS THIRD QUARTER 2025 RESULTS AND UPDATES FULL-YEAR 2025 GUIDANCE

Exhibit 99.1 CVS HEALTH CORPORATION REPORTS THIRD QUARTER 2025 RESULTS AND UPDATES FULL-YEAR 2025 GUIDANCE Financial Highlights •Third quarter total revenues increased to a record high $102.9 billion, up 7.8% compared to prior year •Third quarter GAAP diluted loss per share of $3.13, inclusive of a $5.7 billion goodwill impairment charge related to the Health Care Delivery reporting unit •Third qu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-01011 CVS H

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2025 CVS HEALTH CORPO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2025 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation) (Commission

Letter re: Unaudited Interim Financial Information

Exhibit 15.1 Letter re: Unaudited Interim Financial Information October 29, 2025 To the Shareholders and the Board of Directors of CVS Health Corporation We are aware of the incorporation by reference in the Registration Statements (Form S-3ASR No. 333-272200 and Form S-8 Nos. 333-273611, 333-271582, 333-270936, 333-238507, 333-230035, 333-228622, 333-167746, 333-217853, 333-208805, 333-141481, 33

Omnicare Initiates Voluntary Chapter 11 Process Company Intends to Use Process to Implement a Standalone Restructuring or Sale Strategy Remains Focused on Delivering Safe and Reliable Pharmacy Services to All Customers

EX-99.1 EXHIBIT 99.1 FOR IMMEDIATE RELEASE Omnicare Initiates Voluntary Chapter 11 Process Company Intends to Use Process to Implement a Standalone Restructuring or Sale Strategy Remains Focused on Delivering Safe and Reliable Pharmacy Services to All Customers WOONSOCKET, R.I. – September 22, 2025 – Omnicare, LLC, a subsidiary of CVS Health (NYSE: CVS), today announced it has initiated a voluntar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2025 CVS HEALTH COR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2025 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation) (Commissi

CVS HEALTH CORPORATION No. [•] $[•]

EX-4.4 Exhibit 4.4 UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (“DTC”) TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO., OR TO SUCH O

CVS HEALTH CORPORATION $750,000,000 5.000% Senior Notes due 2032 $1,500,000,000 5.450% Senior Notes due 2035 $1,250,000,000 6.200% Senior Notes due 2055 $500,000,000 6.250% Senior Notes due 2065 Underwriting Agreement

EX-1.1 Exhibit 1.1 CVS HEALTH CORPORATION $750,000,000 5.000% Senior Notes due 2032 $1,500,000,000 5.450% Senior Notes due 2035 $1,250,000,000 6.200% Senior Notes due 2055 $500,000,000 6.250% Senior Notes due 2065 Underwriting Agreement August 11, 2025 Barclays Capital Inc. J.P. Morgan Securities LLC Wells Fargo Securities, LLC As Representatives of the several Underwriters named in Schedule I her

CVS HEALTH CORPORATION No. [•] $[•]

EX-4.2 Exhibit 4.2 UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (“DTC”) TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO., OR TO SUCH O

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 CVS HEALTH CORPOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation) (Commission

CVS HEALTH CORPORATION No. [•] $[•]

EX-4.1 Exhibit 4.1 UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (“DTC”) TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO., OR TO SUCH O

CVS HEALTH CORPORATION No. [•] $[•]

EX-4.3 Exhibit 4.3 UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (“DTC”) TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO., OR TO SUCH O

Security Type

Calculation of Filing Fee Tables S-3 CVS HEALTH Corp Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Debt 5.

CVS HEALTH CORPORATION Pricing Term Sheet — August 11, 2025 $750,000,000 5.000% Senior Notes due 2032 $1,500,000,000 5.450% Senior Notes due 2035 $1,250,000,000 6.200% Senior Notes due 2055 $500,000,000 6.250% Senior Notes due 2065 Issuer: CVS Health

FWP Filed pursuant to Rule 433 Free Writing Prospectus dated August 11, 2025 Registration Statement No.

$4,000,000,000 $750,000,000 5.000% Senior Notes due 2032 $1,500,000,000 5.450% Senior Notes due 2035 $1,250,000,000 6.200% Senior Notes due 2055 $500,000,000 6.250% Senior Notes due 2065

424B2 Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-272200 PROSPECTUS SUPPLEMENT (To Prospectus Dated May 25, 2023) $4,000,000,000 $750,000,000 5.000% Senior Notes due 2032 $1,500,000,000 5.450% Senior Notes due 2035 $1,250,000,000 6.200% Senior Notes due 2055 $500,000,000 6.250% Senior Notes due 2065 This is an offering by CVS Health Corporation of an aggregate of $750,0

Subject to Completion, dated August 11, 2025

424B3 Table of Contents This prospectus supplement relates to an effective registration statement under the Securities Act of 1933, but is not complete and may be changed.

CVS HEALTH CORPORATION REPORTS SECOND QUARTER 2025 RESULTS AND UPDATES FULL-YEAR 2025 GUIDANCE

Exhibit 99.1 CVS HEALTH CORPORATION REPORTS SECOND QUARTER 2025 RESULTS AND UPDATES FULL-YEAR 2025 GUIDANCE Financial Highlights •Second quarter total revenues increased to $98.9 billion, up 8.4% compared to prior year •Second quarter GAAP diluted EPS of $0.80 and Adjusted EPS of $1.81 •Generated year-to-date cash flow from operations of $6.5 billion Operational Highlights •Aetna® delivers distinc

, to the Five Year Credit Agreement dated as of May 11, 2021, by and among the Registrant, the lenders party thereto and Bank of America, N.A., as Administrative Agent.

Exhibit 10.1 Execution Version FOURTH AMENDMENT TO FIVE YEAR CREDIT AGREEMENT FOURTH AMENDMENT TO FIVE YEAR CREDIT AGREEMENT (this “Amendment”), dated as of May 16, 2025, is entered into among CVS Health Corporation, a Delaware corporation (the “Borrower”), the Lenders party hereto and Bank of America, N.A., as Administrative Agent. Except as otherwise provided herein, capitalized terms used herei

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 CVS HEALTH CORPORAT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-01011 CVS HEALTH

Letter from Ernst & Young LLP acknowledging awareness of the use of a report dated

Exhibit 15.1 Letter re: Unaudited Interim Financial Information July 31, 2025 To the Shareholders and the Board of Directors of CVS Health Corporation We are aware of the incorporation by reference in the Registration Statements (Form S-3ASR No. 333-272200 and Form S-8 Nos. 333-273611, 333-271582, 333-270936, 333-238507, 333-230035, 333-228622, 333-167746, 333-217853, 333-208805, 333-141481, 333-1

Form of Registrant’s Performance Stock Unit Agreement between the Registrant and selected employees of the Registrant.

Exhibit 10.2 CVS HEALTH CORPORATION PERFORMANCE STOCK UNIT AGREEMENT GRANT DATE: %%OPTIONDATE,'Month DD, YYYY'%-% 1.GRANT OF AWARD. Pursuant and subject to the provisions of the 2017 Incentive Compensation Plan of CVS Health Corporation (the “Plan”), on the date set forth above (the “Grant Date”), CVS Health Corporation (the “Company”) has granted and hereby evidences by the Performance Stock Unit

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number: 001-01011 A. Full title of the plan a

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2025 (May 15, 2025) CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation)

Restrictive Covenant Agreement dated August 28, 2024 between the Registrant and Heidi B

Exhibit 10.3 CVS Pharmacy, Inc. Restrictive Covenant Agreement I, Heidi B. Capozzi, enter into this Restrictive Covenant Agreement (“Agreement”) with CVS Pharmacy, Inc., on its own behalf and on behalf of its subsidiaries and affiliates (“CVS”), which is effective as of the date I sign the Agreement (“Effective Date”). 1.Consideration for Agreement. In connection with my duties and responsibilitie

Restrictive Covenant Agreement dated January 25, 2023 between the Registrant and J. David Joyner.

Exhibit 10.1 CVS Pharmacy, Inc. Restrictive Covenant Agreement I, John Joyner, enter into this Restrictive Covenant Agreement (“Agreement”) with CVS Pharmacy, Inc., on its own behalf and on behalf of its subsidiaries and affiliates (“CVS”), which is effective as of the date I sign the Agreement (“Effective Date”). 1.Consideration for Agreement. In connection with my duties and responsibilities at

CVS HEALTH CORPORATION REPORTS FIRST QUARTER 2025 RESULTS AND UPDATES FULL-YEAR 2025 GUIDANCE

Exhibit 99.1 CVS HEALTH CORPORATION REPORTS FIRST QUARTER 2025 RESULTS AND UPDATES FULL-YEAR 2025 GUIDANCE First Quarter Financial Highlights •Total revenues increased to $94.6 billion, up 7.0% compared to prior year •GAAP diluted EPS of $1.41 and Adjusted EPS of $2.25 •Generated cash flow from operations of $4.6 billion Operational Highlights •CVS Health to exit the individual exchange business •

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-01011 CVS HEALT

Change in Control Agreement effective as of August 26, 2024 between the Registrant and Heidi B

Exhibit 10.4 CVS HEALTH CORPORATION Change in Control Agreement for Heidi B. Capozzi Confidential Revised 2020 Page 1. Definitions 1 2. Term of Agreement 4 3. Entitlement to Severance Benefit 5 4. Confidentiality; Cooperation with Regard to Litigation; Non-disparagement 7 5. Non-solicitation 8 6. Remedies 8 7. Effect of Agreement on Other Benefits 9 8. Not an Employment Agreement 9 9. Resolution o

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2025 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation) (Commission File

Letter from Ernst & Young LLP acknowledging awareness of the use of a report dated

Exhibit 15.1 Letter re: Unaudited Interim Financial Information May 1, 2025 To the Shareholders and the Board of Directors of CVS Health Corporation We are aware of the incorporation by reference in the Registration Statements (Form S-3ASR No. 333-272200 and Form S-8 Nos. 333-273611, 333-271582, 333-270936, 333-238507, 333-230035, 333-228622, 333-167746, 333-217853, 333-208805, 333-141481, 333-139

between the Registrant and J. David Joyner.

Exhibit 10.2 CVS HEALTH CORPORATION Change in Control Agreement for J. David Joyner Confidential Revised 2020 Page 1. Definitions 1 2. Term of Agreement 4 3. Entitlement to Severance Benefit 5 4. Confidentiality; Cooperation with Regard to Litigation; Non-disparagement 7 5. Non-solicitation 8 6. Remedies 8 7. Effect of Agreement on Other Benefits 9 8. Not an Employment Agreement 9 9. Resolution of

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 7, 2025 CVS HEALTH CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-01011 05-0494040 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

-2-

Exhibit 99.1 PRESS RELEASE CVS Health Announces Chief Financial Officer Transition Plan; Appoints Chief Medical Officer WOONSOCKET, RI (DATE) – CVS Health (NYSE: CVS) today announced two leadership updates. • Brian O. Newman has been named executive vice president and chief financial officer designate, effective April 21. He will succeed CVS Health’s current executive vice president and chief fina

2024 ANNUAL REPORT TO SECURITY HOLDERS

2024 Annual Report Simply better health. CVS Health One CVS Drive Woonsocket, RI 02895 401-765-1500 CVSHealth.com The Forest Stewardship Council® is an international nongovernmental organization that promotes environmentally appropriate, socially beneficial and economically viable management of the world’s forests. To learn more, visit www.FSC.org Environmental impact estimates were calculated usi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )

CVS HEALTH CORPORATION DEFA 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

Message from Our Executive Chair, Our Chief Executive Officer and Our Lead Independent Director Table of Contents Notice of Annual Meeting of Stockholders CVS Health at a Glance Proxy Statement Highlights Corporate Governance and Related Matters Aud

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

The Registrant’s Amended and Restated Severance Plan for Non-Store Employees dated

Exhibit 10.52 CVS HEALTH SEVERANCE PLAN FOR NON-STORE EMPLOYEES (Amended and Restated as of January 1, 2025) CVS HEALTH SEVERANCE PLAN FOR NON-STORE EMPLOYEES (Amended and Restated as of January 1, 2025) WHEREAS, CVS Health Corporation (the “Company”) has established the CVS Health Severance Plan for Non-Store Employees (the “Plan”) to provide financial assistance to employees in non-store positio

Material terms of outstanding securities that are registered under Section 12 of the 1934 Act as required by Item 202(a)-(d) and (f) of Regulation S-K.

Exhibit 4.38 DESCRIPTION OF COMMON STOCK REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description (this “Description”) of the terms of the common stock of CVS Health Corporation (“CVS Health”) is a summary only and is qualified by reference to the relevant provisions of Delaware law and the Restated Certificate of Incorporation (the “Charter”) and the By-Laws (t

CVS HEALTH CORPORATION REPORTS FOURTH QUARTER AND FULL-YEAR 2024 RESULTS

Exhibit 99.1 CVS HEALTH CORPORATION REPORTS FOURTH QUARTER AND FULL-YEAR 2024 RESULTS Fourth Quarter Highlights •Total revenues increased to $97.7 billion, up 4.2% compared to prior year •GAAP diluted EPS of $1.30 and Adjusted EPS of $1.19 Full-Year Highlights •Total revenues increased to $372.8 billion, up 4.2% compared to prior year •GAAP diluted EPS of $3.66 and Adjusted EPS of $5.42 •Generated

Subsidiaries of CVS Health Corporation.

Exhibit 21.1 Subsidiaries of CVS Health Corporation Listed below are subsidiaries under CVS Health Corporation at December 31, 2024 with their jurisdictions of organization shown in parentheses. Subsidiaries excluded from the list below are not insurance companies and would not, in the aggregate, constitute a “significant subsidiary” of CVS Health Corporation, as that term is defined in Rule 1-02(

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-01011 CVS HEALTH COR

Stock Option Agreement between the Registrant and selected executives of the Registrant.

Exhibit 10.35 CVS HEALTH CORPORATION NONQUALIFIED STOCK OPTION AGREEMENT GRANT DATE: %%OPTIONDATE,'Month DD, YYYY'%-% 1.GRANT OF AWARD. Pursuant and subject to the provisions of the 2017 Incentive Compensation Plan of CVS Health Corporation (the “Plan”), on the date set forth above (the “Grant Date”), CVS Health Corporation (the “Company”) has granted and hereby evidences the award to the person n

Securities Trading Policy of CVS Health Corporation, as amended January 28, 2025.

Exhibit 19.1 CVS HEALTH CORPORATION SECURITIES TRADING POLICY (Amended as of January 28, 2025) The Need for a Policy This Policy has been developed: ▪To educate the Company’s personnel; ▪To set forth guidelines for courses of action for the Company and its personnel; ▪To protect the Company and each of its personnel against legal liability; and ▪To preserve the reputation of the Company and its pe

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2025 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation) (Commissio

Oak Street Health, Inc. Omnibus Incentive Plan, as amended.

Exhibit 10.27 OAK STREET HEALTH, INC. OMNIBUS INCENTIVE PLAN As Amended July 28, 2023 ARTICLE I PURPOSE; EFFECTIVE DATE; TERM 1.1 Purpose. The purpose of this Oak Street Health, Inc. Omnibus Incentive Plan is to enhance the profitability and value of the Company for the benefit of its Stockholders by enabling the Company to offer Eligible Individuals stock- and cash-based incentives in order to at

Promotion Grant Award Agreement dated November 30, 2024 between the Registrant and J. David Joyner.

Exhibit 10.68 CVS HEALTH CORPORATION PROMOTION GRANT PREMIUM PRICED NQSO/SAR AWARD AGREEMENT GRANT DATE: November 30, 2024 1.GRANT OF AWARD. Pursuant and subject to the provisions of the 2017 Incentive Compensation Plan of CVS Health Corporation (the “Plan”), on the date set forth above (the “Grant Date”), CVS Health Corporation (the “Company”) has granted and hereby evidences the award to the per

The Registrant’s Management Incentive Plan.

Exhibit 10.51 CVS Health Corporation Management Incentive Plan I. Objectives and Summary CVS Health Corporation’s Management Incentive Plan (the “MIP”) is designed to reward Eligible Participants of CVS Health Corporation and its subsidiaries (together, “the Company”) for their role in driving performance and to encourage Eligible Participants’ continued employment with the Company. Funding for th

Separation and Advisory Services Letter Agreement dated October 17, 2024 between the Registrant and Karen S. Lynch

EXHIBIT 10.67 EXECUTION VERSION CVS HEALTH CORPORATION October 17, 2024 Karen S. Lynch Address on file at the Company Dear Karen: The Board appreciates your dedicated service and contributions as President and Chief Executive Officer of CVS Health Corporation (the “Company”). This letter (this “Letter Agreement”) memorializes our recent discussions and agreement concerning your separation from you

The Registrant’s Executive Health Program Summary and Program Document effective September 20, 2023.

Exhibit 10.53 CVS Health Executive Health Program Summary and Program Document Effective September 20, 2023 Purpose The CVS Health Executive Health Program (“Program”) is established effective September 20, 2023. Its overall purpose is to provide a comprehensive annual health examination and assessment to eligible executives and/or officers of CVS Health or a participating employer (the “Company”)

CVS Health Corporation Announces Pricing of Maximum Tender Offer

EX-99.2 Exhibit 99.2 Investor Larry McGrath Media Ethan Slavin Contact: Executive Vice President Contact: 860-273-6095 Chief Strategy Officer & Chief Strategic Advisor to the CEO [email protected] [email protected] FOR IMMEDIATE RELEASE CVS Health Corporation Announces Pricing of Maximum Tender Offer WOONSOCKET, RI, December 16, 2024 – CVS Health Corporation (“CVS Health” or the

CVS Health Corporation Announces Early Results of Maximum Tender Offer and Election of Early Settlement

EX-99.1 Exhibit 99.1 Investor Larry McGrath Media Ethan Slavin Contact: Executive Vice President Contact: 860-273-6095 Chief Strategy Officer & Chief Strategic Advisor to the CEO [email protected] [email protected] FOR IMMEDIATE RELEASE CVS Health Corporation Announces Early Results of Maximum Tender Offer and Election of Early Settlement WOONSOCKET, RI, December 16, 2024– CVS He

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2024 CVS HEALTH CORP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2024 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation) (Commissio

New York Mellon Trust Company, N.A. (as successor to The Bank of New York Trust Company, N

Exhibit 4.1 CVS CAREMARK CORPORATION, Company and THE BANK OF NEW YORK TRUST COMPANY, N.A., Trustee SUBORDINATED INDENTURE Dated as of May 25, 2007 CROSS-REFERENCE TABLE Trust Indenture Act Section Indenture Section 310 (a)(1) 7.10 (a)(2) 7.10 (a)(3) N/A (a)(4) N/A (a)(5) 7.10 (b) 7.10 (c) N/A 311 (a) 7.11 (b) 7.11 (c) N/A 312 (a) 2.05 (b) 10.03 (c) 10.03 313 (a) 7.06 (b)(1) 7.06 (b)(2) 7.06 (e) 7

Supplemental Indenture, dated as of December 10, 2024, between the Registrant and the Bank of New York Mellon Trust Company, N.A. (incorporated by reference to Exhibit 4.

Exhibit 4.3 THIRD SUPPLEMENTAL INDENTURE BETWEEN CVS HEALTH CORPORATION ISSUER AND THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A. TRUSTEE DATED AS OF DECEMBER 10, 2024 6.750% FIXED-TO-FIXED RATE SERIES B JUNIOR SUBORDINATED NOTES DUE 2054 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 1.1 Definition of Terms 1 ARTICLE II GENERAL TERMS AND CONDITIONS OF THE NOTES 4 2.1 Designation and Principal Am

econd Supplemental Indenture, dated as of December 10, 2024, between the

Exhibit 4.2 SECOND SUPPLEMENTAL INDENTURE BETWEEN CVS HEALTH CORPORATION ISSUER AND THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A. TRUSTEE DATED AS OF DECEMBER 10, 2024 7.000% FIXED-TO-FIXED RATE SERIES A JUNIOR SUBORDINATED NOTES DUE 2055 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 1.1 Definition of Terms 1 ARTICLE II GENERAL TERMS AND CONDITIONS OF THE NOTES 4 2.1 Designation and Principal A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2024 CVS HEALTH CORP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2024 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation) (Commissio

CVS Health Corporation Announces Expiration and Results of Any and All Tender Offer

Exhibit 99.1 Investor Larry McGrath Media Ethan Slavin Contact: Executive Vice President Chief Strategy Officer & Chief Strategic Advisor to the CEO  [email protected] Contact: 860-273-6095 [email protected] FOR IMMEDIATE RELEASE CVS Health Corporation Announces Expiration and Results of Any and All Tender Offer WOONSOCKET, RI, December 9, 2024 – CVS Health Corporation (“CVS Heal

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2024 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation) (Commission

CVS Health Corporation Announces Pricing of Any and All Tender Offer

Exhibit 99.1 Investor Larry McGrath Media Ethan Slavin Contact: Executive Vice President Contact: 860-273-6095 Chief Strategy Officer & [email protected] Chief Strategic Advisor to the CEO [email protected] FOR IMMEDIATE RELEASE CVS Health Corporation Announces Pricing of Any and All Tender Offer WOONSOCKET, RI, December 6, 2024 – CVS Health Corporation (“CVS Health”, NYSE: CVS)

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2024 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation) (Commission

Underwriting Agreement, dated December 3, 2024, between CVS Health Corporation and Barclays Capital Inc., Citigroup Global Markets Inc. and Goldman Sachs & Co. LLC, as representatives of the several Underwriters named in Schedule I thereto.

Exhibit 1.1 CVS HEALTH CORPORATION $2,250,000,000 7.000% Series A Junior Subordinated Notes due 2055 $750,000,000 6.750% Series B Junior Subordinated Notes due 2054 Underwriting Agreement December 3, 2024 Barclays Capital Inc. Citigroup Global Markets Inc. Goldman Sachs & Co. LLC As Representatives of the several Underwriters named in Schedule I hereto c/o Barclays Capital Inc. 745 Seventh Avenue

$3,000,000,000 $2,250,000,000 7.000% Fixed-to-Fixed Rate Series A Junior Subordinated Notes due 2055 $750,000,000 6.750% Fixed-to-Fixed Rate Series B Junior Subordinated Notes due 2054

Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-272200 PROSPECTUS SUPPLEMENT (To Prospectus Dated May 25, 2023) $3,000,000,000 $2,250,000,000 7.000% Fixed-to-Fixed Rate Series A Junior Subordinated Notes due 2055 $750,000,000 6.750% Fixed-to-Fixed Rate Series B Junior Subordinated Notes due 2054 This is an offering by CVS Health Corporation (“we”, “us” or “our”) of an aggre

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2024 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation) (Commission

Calculation of Filing Fee Tables ● 12/5/2024 Form 424(b)(2) (Form Type) CVS Health Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

Exhibit 107 Calculation of Filing Fee Tables ● 12/5/2024 Form 424(b)(2) (Form Type) CVS Health Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Debt 7.

CVS HEALTH CORPORATION Pricing Term Sheet—December 3, 2024 $2,250,000,000 7.000% Series A Junior Subordinated Notes due 2055 $750,000,000 6.750% Series B Junior Subordinated Notes due 2054 Issuer: CVS Health Corporation (the “Issuer”) Description of

FWP Filed pursuant to Rule 433 Free Writing Prospectus dated December 3, 2024 Registration Statement No.

Subject to Completion, dated December 3, 2024

Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-272200 This prospectus supplement relates to an effective registration statement under the Securities Act of 1933, but is not complete and may be changed. This prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any jurisdict

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2024 CVS HEALTH CORPO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2024 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation) (Commission

CVS Health Corporation Announces Cash Tender Offers for Certain of its and Aetna’s Outstanding Notes

Exhibit 99.1 Investor Larry McGrath Media Ethan Slavin Contact: Executive Vice President Contact: 860-273-6095 Chief Strategy Officer & [email protected] Chief Strategic Advisor to the CEO [email protected] FOR IMMEDIATE RELEASE CVS Health Corporation Announces Cash Tender Offers for Certain of its and Aetna’s Outstanding Notes WOONSOCKET, RI, December 2, 2024 – CVS Health Corpor

LETTER

November 21, 2024 Thomas F. Cowhey Executive Vice President and Chief Financial Officer CVS Health Corporation One CVS Drive Woonsocket, RI 02895 Re: CVS Health Corporation Form 10-K for Fiscal Year Ended December 31, 2023 File No. 001-01011 Dear Thomas F. Cowhey: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and ade

By EDGAR

By EDGAR November 21, 2024 Valeria Franks and Angela Lumley U.S. Securities and Exchange Commission Division of Corporation Finance Office of Trade & Services 100 F Street, NE Washington, D.C. 20549-0405 Re: CVS Health Corporation Form 10-K for Fiscal Year Ended December 31, 2023 File No. 001-01011 Dear Mses. Franks and Lumley: CVS Health Corporation (the “Company”) is responding to the comment le

LETTER

November 19, 2024 Thomas F. Cowhey Executive Vice President and Chief Financial Officer CVS Health Corporation One CVS Drive Woonsocket, RI 02895 Re: CVS Health Corporation Form 10-K for Fiscal Year Ended December 31, 2023 File No. 001-01011 Dear Thomas F. Cowhey: We have reviewed your filing and have the following comment(s). Please respond to this letter within ten business days by providing the

Agreement, dated November 17, 2024, by and between the R

EX-10.1 Exhibit 10.1 CVS Health Corporation November 17, 2024 Glenview Capital Management, LLC 767 Fifth Avenue, 44th Floor New York, NY 10153 Attention: Mark Horowitz Email: [email protected] Ladies and Gentlemen: CVS Health Corporation, a Delaware corporation (the “Company”), and Glenview Capital Management, LLC (together with its Affiliates, “Counterparty” or “you”, and together with the

CVS Health Announces Board Appointments

EX-99.1 Exhibit 99.1 PRESS RELEASE CVS Health Announces Board Appointments CVS Health Board of Directors appoints four new members: Leslie Norwalk, Larry Robbins, Guy Sansone, and Doug Shulman Appointments follow productive engagement with Glenview Capital Management WOONSOCKET, RI (November 18, 2024) – The Board of Directors of CVS Health (NYSE: CVS) today announced the appointment of four new bo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 12, 2024 CVS HEALTH CORPOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 12, 2024 CVS HEALTH CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-01011 05-0494040 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

CVS / CVS Health Corporation / DODGE & COX - SC 13G Passive Investment

SC 13G 1 d793980dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 0 )* CVS HEALTH CORPORATION (Name of Issuer) Common Stock (Title of Class of Securities) 126650100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-01011 CVS H

CVS HEALTH CORPORATION REPORTS THIRD QUARTER 2024 RESULTS

Exhibit 99.1 CVS HEALTH CORPORATION REPORTS THIRD QUARTER 2024 RESULTS Financial Highlights •Third quarter total revenues increased to $95.4 billion, up 6.3% compared to the prior year •Third quarter GAAP diluted EPS of $0.07 and Adjusted EPS of $1.09 •Third quarter GAAP diluted EPS and Adjusted EPS include charges to record premium deficiency reserves of approximately $1.1 billion ($0.63 per shar

Letter from Ernst & Young LLP acknowledging awareness of the use of a report dated

Exhibit 15.1 Letter re: Unaudited Interim Financial Information November 6, 2024 To the Shareholders and the Board of Directors of CVS Health Corporation We are aware of the incorporation by reference in the Registration Statements (Form S-3ASR No. 333-272200 and Form S-8 Nos. 333-273611, 333-271582, 333-270936, 333-238507, 333-230035, 333-228622, 333-167746, 333-217853, 333-208805, 333-141481, 33

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 CVS HEALTH CORPO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation) (Commission

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 6, 2024 CVS HEALTH CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-01011 05-0494040 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

CVS Health Announces Leadership Appointments

EX-99.1 Exhibit 99.1 PRESS RELEASE CVS Health Announces Leadership Appointments Prem Shah named Group President, CVS Health; Steve Nelson named President, Aetna WOONSOCKET, RI (November 6, 2024) – CVS Health (NYSE: CVS) today announced Prem Shah will be Group President, and will continue to report to David Joyner, President and Chief Executive Officer. In addition, the company announced the appoin

CVS / CVS Health Corporation / BlackRock, Inc. Passive Investment

SC 13G/A 1 us1266501006102424.txt us1266501006102424.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 12) CVS HEALTH CORPORATION - (Name of Issuer) Common Stock - (Title of Class of Securities) 126650100 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropria

CVS Health Appoints David Joyner President and Chief Executive Officer

EX-99.1 Exhibit 99.1 PRESS RELEASE CVS Health Appoints David Joyner President and Chief Executive Officer Roger Farah Named Executive Chairman of the Board Company provides preliminary guidance for third quarter 2024 GAAP diluted Earnings per Share (EPS) of $0.03 to $0.08 and Adjusted EPS of $1.05 to $1.10 WOONSOCKET, RI (October 18, 2024) – CVS Health (NYSE: CVS) today announced that David Joyner

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 17, 2024 CVS HEALTH CORPORA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 17, 2024 CVS HEALTH CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-01011 05-0494040 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

Third Amendment to Five Year Credit Agreement dated as of May 16, 2024, to the Five Year Credit Agreement dated as of May 16, 2019, as amended by the Second Amendment to Five Year Credit Agreement, dated as of March 23, 2023, as amended by the First Amendment to Five Year Credit Agreement, dated as of May 16, 2022,by and among the Registrant, the lenders party thereto and Bank of America, N.A., as Administrative Agent (incorporated by reference to Exhibit 10.

Exhibit 10.1 Execution Version THIRD AMENDMENT TO FIVE YEAR CREDIT AGREEMENT THIRD AMENDMENT TO FIVE YEAR CREDIT AGREEMENT (this “Amendment”), dated as of May 16, 2024, is entered into among CVS Health Corporation, a Delaware corporation (the “Borrower”), the Lenders party hereto and Bank of America, N.A., as Administrative Agent. Except as otherwise provided herein, capitalized terms used herein

Second Amendment to Five Year Credit Agreement dated as of May 16, 2024, to the Five Year Credit Agreement dated as of May 16, 2022, as amended by the First Amendment to Five Year Credit Agreement, dated as of March 23, 2023, by and among the Registrant, the lenders party thereto and Bank of America, N.A., as Administrative Agent (incorporated by reference to Exhibit 10.3 to the Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024).

Exhibit 10.3 Execution Version SECOND AMENDMENT TO FIVE YEAR CREDIT AGREEMENT SECOND AMENDMENT TO FIVE YEAR CREDIT AGREEMENT (this “Amendment”), dated as of May 16, 2024, is entered into among CVS Health Corporation, a Delaware corporation (the “Borrower”), the Lenders party hereto and Bank of America, N.A., as Administrative Agent. Except as otherwise provided herein, capitalized terms used herei

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 CVS HEALTH CORPORA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation) (Commission F

Third Amendment to Five Year Credit Agreement dated as of May 16, 2024, to the Five Year Credit Agreement dated as of May 11, 2021, as amended by the Second Amendment to Five Year Credit Agreement, dated as of March 23, 2023,as amended by the First Amendment to Five Year Credit Agreement, dated as of May 16, 2022, by and among the Registrant, the lenders party thereto and Bank of America, N.A., as Administrative Agent (incorporated by reference to Exhibit 10.

Exhibit 10.2 Execution Version THIRD AMENDMENT TO FIVE YEAR CREDIT AGREEMENT THIRD AMENDMENT TO FIVE YEAR CREDIT AGREEMENT (this “Amendment”), dated as of May 16, 2024, is entered into among CVS Health Corporation, a Delaware corporation (the “Borrower”), the Lenders party hereto and Bank of America, N.A., as Administrative Agent. Except as otherwise provided herein, capitalized terms used herein

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-01011 CVS HEALTH

Letter from Ernst & Young LLP acknowledging awareness of the use of a report dated

Exhibit 15.1 Letter re: Unaudited Interim Financial Information August 7, 2024 To the Shareholders and the Board of Directors of CVS Health Corporation We are aware of the incorporation by reference in the Registration Statements (Form S-3ASR No. 333-272200 and Form S-8 Nos. 333-273611, 333-271582, 333-270936, 333-238507, 333-230035, 333-228622, 333-167746, 333-217853, 333-208805, 333-141481, 333-

CVS HEALTH CORPORATION REPORTS SECOND QUARTER 2024 RESULTS AND REVISES FULL-YEAR 2024 GUIDANCE

Exhibit 99.1 CVS HEALTH CORPORATION REPORTS SECOND QUARTER 2024 RESULTS AND REVISES FULL-YEAR 2024 GUIDANCE Financial Highlights •Second quarter total revenues increased to $91.2 billion, up 2.6% compared to the prior year •Second quarter GAAP diluted EPS of $1.41 and Adjusted EPS of $1.83 •Generated year-to-date cash flow from operations of $8.0 billion 2024 Full-Year Guidance •Revised GAAP dilut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number: 001-01011 A. Full title of the plan a

Filing Fee Table.

Exhibit 107.1 CALCULATION OF FILING FEE TABLE S-8 (Form Type) CVS Health Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Class A Common Stock, $0.01 par

As filed with the Securities and Exchange Commission on May 22, 2024

As filed with the Securities and Exchange Commission on May 22, 2024 Registration No.

2017 Incentive Compensation Plan of CVS Health Corporation.

Exhibit 99.1 2017 Incentive Compensation Plan of CVS Health Corporation As Amended Through March 21, 2024 1. Purpose. The purpose of this 2017 Incentive Compensation Plan (the “Plan”) is to assist CVS Health Corporation, a Delaware corporation (the “Corporation”), and its subsidiaries, in attracting, retaining and rewarding high-quality executives, employees, and other persons who provide services

Letter of Acknowledgement from Ernst & Young LLP re: Unaudited Interim Financial Information

EXHIBIT 15 May 22, 2024 The Board of Directors and Shareholders CVS Health Corporation Letter re: Unaudited Interim Financial Information We are aware of the incorporation by reference in this Registration Statement (Form S-8) of CVS Health Corporation pertaining to the 2017 Incentive Compensation Plan of CVS Health Corporation of our report dated May 1, 2024, relating to the unaudited condensed consolidated interim financial statements of CVS Health Corporation that are included in its Form 10-Q for the quarter ended March 31, 2024.

2017 Incentive Compensation Plan of CVS Health Corporation, as amende

Exhibit 10.1 2017 Incentive Compensation Plan of CVS Health Corporation 1.Purpose. The purpose of this 2017 Incentive Compensation Plan (the “Plan”) is to assist CVS Health Corporation, a Delaware corporation (the “Corporation”), and its subsidiaries, in attracting, retaining and rewarding high-quality executives, employees, and other persons who provide services to the Corporation and/or its subs

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2024 (May 16, 2024) CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation)

Forms of award agreements to be used under Registrant’s 2017 Incentive Compensation Plan, as amended (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed May 22, 2024).

Exhibit 10.2 CVS HEALTH CORPORATION PERFORMANCE STOCK UNIT AGREEMENT GRANT DATE: %%OPTIONDATE,'Month DD, YYYY'%-% 1.GRANT OF AWARD. Pursuant and subject to the provisions of the 2017 Incentive Compensation Plan of CVS Health Corporation (the “Plan”), on the date set forth above (the “Grant Date”), CVS Health Corporation (the “Company”) has granted and hereby evidences by the Performance Stock Unit

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation) (Commission File

Form of the 2029 Note.

Exhibit 4.1 UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (“DTC”) TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO., OR TO SUCH OTHER EN

Form of the 2054 Note.

Exhibit 4.5 UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (“DTC”) TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO., OR TO SUCH OTHER EN

Form of the 2031 Note.

Exhibit 4.2 UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (“DTC”) TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO., OR TO SUCH OTHER EN

Form of the 2044 Note.

Exhibit 4.4 UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (“DTC”) TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO., OR TO SUCH OTHER EN

Form of the 2034 Note.

Exhibit 4.3 UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (“DTC”) TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO., OR TO SUCH OTHER EN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 CVS HEALTH CORPORATIO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation) (Commission File

Underwriting Agreement dated May 7, 2024, among CVS Health Corporation and BofA Securities, Inc., Barclays Capital Inc., Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Wells Fargo Securities, LLC as representatives of the several Underwriters named in Schedule I thereto.

Exhibit 1.1 CVS HEALTH CORPORATION $1,000,000,000 5.400% Senior Notes due 2029 $1,000,000,000 5.550% Senior Notes due 2031 $1,250,000,000 5.700% Senior Notes due 2034 $750,000,000 6.000% Senior Notes due 2044 $1,000,000,000 6.050% Senior Notes due 2054 Underwriting Agreement May 7, 2024 BofA Securities, Inc. Barclays Capital Inc. Goldman Sachs & Co. LLC J.P. Morgan Securities LLC Wells Fargo Secur

$5,000,000,000 $1,000,000,000 5.400% Senior Notes due 2029 $1,000,000,000 5.550% Senior Notes due 2031 $1,250,000,000 5.700% Senior Notes due 2034   $750,000,000 6.000% Senior Notes due 2044 $1,000,000,000 6.050% Senior Notes due 2054

Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-272200 PROSPECTUS SUPPLEMENT (To Prospectus Dated May 25, 2023) $5,000,000,000 $1,000,000,000 5.400% Senior Notes due 2029 $1,000,000,000 5.550% Senior Notes due 2031 $1,250,000,000 5.700% Senior Notes due 2034   $750,000,000 6.000% Senior Notes due 2044 $1,000,000,000 6.050% Senior Notes due 2054 This is an offering by CVS He

CALCULATION OF FILING FEE TABLE (Form Type) CVS Health Corporation (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities         Security  Type Security Class Title Calculation  Fee or Forward Carry Rule Amount R

Exhibit 107 CALCULATION OF FILING FEE TABLE 424(b)(2) (Form Type) CVS Health Corporation (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities         Security  Type Security Class Title Calculation  Fee or Forward Carry Rule Amount Registered Proposed Maximum Offering Price per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Debt 5.

CVS HEALTH CORPORATION Pricing Term Sheet—May 7, 2024 $1,000,000,000 5.400% Senior Notes due 2029 $1,000,000,000 5.550% Senior Notes due 2031 $1,250,000,000 5.700% Senior Notes due 2034 $750,000,000 6.000% Senior Notes due 2044 $1,000,000,000 6.050%

FWP Filed pursuant to Rule 433 Free Writing Prospectus dated May 7, 2024 Registration Statement No.

Subject to Completion, dated May 7, 2024

424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-272200 Subject to Completion, dated May 7, 2024 This prospectus supplement relates to an effective registration statement under the Securities Act of 1933, but is not complete and may be changed. This prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an

Letter from Ernst & Young LLP acknowledging awareness of the use of a report dated

Exhibit 15.1 Letter re: Unaudited Interim Financial Information May 1, 2024 To the Shareholders and the Board of Directors of CVS Health Corporation We are aware of the incorporation by reference in the Registration Statements (Form S-3ASR No. 333-272200 and Form S-8 Nos. 333-273611, 333-271582, 333-270936, 333-238507, 333-230035, 333-228622, 333-167746, 333-217853, 333-208805, 333-141481, 333-139

CVS HEALTH CORPORATION REPORTS FIRST QUARTER 2024 RESULTS AND REVISES FULL-YEAR 2024 GUIDANCE

Exhibit 99.1 CVS HEALTH CORPORATION REPORTS FIRST QUARTER 2024 RESULTS AND REVISES FULL-YEAR 2024 GUIDANCE First Quarter Highlights •Total revenues increased to $88.4 billion, up 3.7% compared to prior year •GAAP diluted EPS of $0.88 and Adjusted EPS of $1.31 •Generated cash flow from operations of $4.9 billion 2024 Full-Year Guidance •Revised GAAP diluted EPS guidance to at least $5.64 from at le

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2024 CVS HEALTH CORPORATIO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2024 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation) (Commission File

Restrictive Covenant Agreement dated J

Exhibit 10.1 CVS Pharmacy, Inc. Restrictive Covenant Agreement I, Samrat Khichi, enter into this Restrictive Covenant Agreement (“Agreement”) with CVS Pharmacy, Inc., on its own behalf and on behalf of its subsidiaries and affiliates (“CVS”), which is effective as of the date I sign the Agreement (“Effective Date”). 1.Consideration for Agreement. In connection with my duties and responsibilities a

Term Loan Credit Agreement, dated March 25, 2024, by and among the Registrant, the lenders party thereto and Bank of America, N.A., as administrative agent.

Exhibit 10.3 Execution Version Deal CUSIP: 23242UBB8 Facility CUSIP: 23242UBC6 364-DAY TERM LOAN CREDIT AGREEMENT by and among CVS HEALTH CORPORATION, THE LENDERS PARTY HERETO, BARCLAYS BANK PLC and JPMORGAN CHASE BANK, N.A., as Co-Syndication Agents, GOLDMAN SACHS BANK USA and WELLS FARGO BANK, NATIONAL ASSOCIATION, as Co-Documentation Agents, and BANK OF AMERICA, N.A., as Administrative Agent Da

Change in Control Agreement effective as of

Exhibit 10.2 CVS HEALTH CORPORATION Change in Control Agreement for SAMRAT KHICHI CONFIDENTIAL Revised 2020 Page 1. Definitions 1 2. Term of Agreement 4 3. Entitlement to Severance Benefit 5 4. Confidentiality; Cooperation with Regard to Litigation; Non-disparagement 7 5. Non-solicitation 8 6. Remedies 8 7. Effect of Agreement on Other Benefits 9 8. Not an Employment Agreement 9 9. Resolution of D

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-01011 CVS HEALT

NOTICE OF EXEMPT SOLICITATION

NOTICE OF EXEMPT SOLICITATION Name of the registrant: CVS Health Corporation Name of person relying on exemption: New York State Comptroller Thomas P.

Notice of Annual Meeting of Stockholders and Proxy Statement Our Vision Message from Our Independent Chair and Chief Executive Officer Table of Contents Notice of Annual Meeting of Stockholders The Value We Create Our Purpose: Bringing our heart to e

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

COURTESY PDF OF PROXY STATEMENT

2024 Notice of Annual Meeting of Stockholders and Proxy Statement May 16, 2024 | Virtual Meeting at 8:00 a.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

ANNUAL REPORT TO SECURITY HOLDERS

2023 Annual Report Building a world of health around every consumer.Officer, Director and Stockholder Information Officers Fernando Aguirre (1) (3) (5) Former Chairman and Chief Executive Officer, Chiquita Brands International, Inc. Jeffrey R. Balser, M.D., Ph.D. (1) (2) President and Chief Executive Officer, Vanderbilt University Medical Center C. David Brown II (3) (4) (5) Partner and Former Mem

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2024 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation) (Commission Fi

CVS / CVS Health Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv0723-cvshealthcorp.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: CVS Health Corp Title of Class of Securities: Common Stock CUSIP Number: 126650100 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the r

Oak Street Health, Inc. Omnibus Incentive Plan, as amended.

Exhibit 10.22 OAK STREET HEALTH, INC. OMNIBUS INCENTIVE PLAN As Amended July 28, 2023 ARTICLE I PURPOSE; EFFECTIVE DATE; TERM 1.1 Purpose. The purpose of this Oak Street Health, Inc. Omnibus Incentive Plan is to enhance the profitability and value of the Company for the benefit of its Stockholders by enabling the Company to offer Eligible Individuals stock- and cash-based incentives in order to at

The Registrant’s Executive Health Program Summary and Program Document effective September 20, 2023.

Exhibit 10.47 CVS Health Executive Health Program Summary and Program Document Effective September 20, 2023 Purpose The CVS Health Executive Health Program (“Program”) is established effective September 20, 2023. Its overall purpose is to provide a comprehensive annual health examination and assessment to eligible executives and/or officers of CVS Health or a participating employer (the “Company”)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-01011 CVS HEALTH COR

Material terms of outstanding securities that are registered under Section 12 of the 1934 Act as required by Item 202(a)-(d) and (f) of Regulation S-K.

Exhibit 4.29 DESCRIPTION OF COMMON STOCK REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description (this “Description”) of the terms of the common stock of CVS Health Corporation (“CVS Health”) is a summary only and is qualified by reference to the relevant provisions of Delaware law and the Restated Certificate of Incorporation (the “Charter”) and the By-Laws (t

The Registrant’s Management Incentive Plan.

Exhibit 10.45 CVS Health Corporation Management Incentive Plan I. Objectives and Summary CVS Health Corporation’s Management Incentive Plan (the “MIP”) is designed to reward Eligible Participants of CVS Health Corporation and its subsidiaries (together, “the Company”) for their role in driving performance and to encourage Eligible Participants’ continued employment with the Company. Funding for th

Change in Control Agreement effective as of January 5, 2024 between the Registrant and Thomas F. Cowhey

Exhibit 10.54 CVS HEALTH CORPORATION Change in Control Agreement for THOMAS F. COWHEY CONFIDENTIAL Revised 2020 Page 1. Definitions 1 2. Term of Agreement 4 3. Entitlement to Severance Benefit 5 4. Confidentiality; Cooperation with Regard to Litigation; Non-disparagement 7 5. Non-solicitation 8 6. Remedies 8 7. Effect of Agreement on Other Benefits 9 8. Not an Employment Agreement 9 9. Resolution

CVS HEALTH REPORTS FOURTH QUARTER AND FULL-YEAR 2023 RESULTS

Exhibit 99.1 CVS HEALTH REPORTS FOURTH QUARTER AND FULL-YEAR 2023 RESULTS WOONSOCKET, RHODE ISLAND, February 7, 2024 - CVS Health Corporation (NYSE: CVS) today announced operating results for the three months and year ended December 31, 2023. FOURTH QUARTER HIGHLIGHTS KEY FINANCIAL DATA •Total revenues increased to $93.8 billion, up 11.9% compared to prior year •GAAP diluted EPS of $1.58 and Adjus

Registrant’s Dodd-Frank Clawback Policy adopted September 21, 2023.

Exhibit 97.1 CVS HEALTH CORPORATION DODD-FRANK CLAWBACK POLICY The Board of Directors (the “Board”) of CVS Health Corporation (the “Company”) has adopted this Dodd-Frank Clawback Policy (this “Policy”) in accordance with the applicable provisions of The New York Stock Exchange Listed Company Manual (the “Clawback Rules”), promulgated pursuant to the final rules adopted by the Securities and Exchan

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2024 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation) (Commission

Subsidiaries of CVS Health Corporation.

Exhibit 21.1 Subsidiaries of CVS Health Corporation Listed below are subsidiaries under CVS Health Corporation at December 31, 2023 with their jurisdictions of organization shown in parentheses. Subsidiaries excluded from the list below are not insurance companies and would not, in the aggregate, constitute a “significant subsidiary” of CVS Health Corporation, as that term is defined in Rule 1-02(

Restrictive Covenant Agreement dated January 7, 2024 between the Registrant and Thomas F. Cowhey

Exhibit 10.53 CVS Pharmacy, Inc. Restrictive Covenant Agreement . I, Thomas F. Cowhey, enter into this Restrictive Covenant Agreement (“Agreement”) with CVS Pharmacy, Inc., on its own behalf and on behalf of its subsidiaries and affiliates (“CVS”), which is effective as of the date I sign the Agreement (“Effective Date”). 1.Consideration for Agreement. In connection with my duties and responsibili

CVS / CVS Health Corporation / BlackRock Inc. Passive Investment

SC 13G/A 1 us1266501006012624.txt us1266501006012624.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 11) CVS HEALTH CORPORATION - (Name of Issuer) Common Stock - (Title of Class of Securities) 126650100 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation) (Commission

CVS Health Announces Leadership Appointments Thomas F. Cowhey Named Chief Financial Officer Mike Pykosz Named President of Health Care Delivery

Exhibit 99.1 CVS Health Announces Leadership Appointments Thomas F. Cowhey Named Chief Financial Officer Mike Pykosz Named President of Health Care Delivery WOONSOCKET, R.I., January 5, 2024 — CVS Health® (NYSE: CVS) today announced several leadership updates, effective immediately: · Senior Vice President of Corporate Finance and interim CFO, Tom Cowhey, has been formally appointed the company’s

CVS Health highlights path to accelerating long-term growth through building a world of health around every consumer

Exhibit 99.1 CVS Health highlights path to accelerating long-term growth through building a world of health around every consumer •Introduces CVS CostVantageTM and CVS Caremark TrueCostTM to drive aligned incentives and deliver a more transparent and sustainable reimbursement model •Launches CVS HealthspireTM brand for Health Services segment that simplifies access to multi-payor capabilities, bet

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2023 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-01011 CVS H

CVS Health reports third quarter results

Exhibit 99.1 CVS Health reports third quarter results WOONSOCKET, RHODE ISLAND, November 1, 2023 - CVS Health Corporation (NYSE: CVS) today announced operating results for the three months ended September 30, 2023. Third quarter highlights Key financial data •Total revenues increased to $89.8 billion, up 10.6% compared to prior year •GAAP diluted EPS of $1.75 and Adjusted EPS of $2.21 Year-to-date

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 CVS HEALTH CORPO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation) (Commission

Letter from Ernst & Young LLP acknowledging awareness of the use of a report dated

Exhibit 15.1 Letter re: Unaudited Interim Financial Information November 1, 2023 To the Shareholders and the Board of Directors of CVS Health Corporation We are aware of the incorporation by reference in the Registration Statements (Form S-3ASR No. 333-272200 and Form S-8 Nos. 333-273611, 333-271582, 333-270936, 333-238507, 333-230035, 333-228622, 333-167746, 333-217853, 333-208805, 333-141481, 33

The Registrant's Amended and Restated Severance Plan for Non-Store Employees dated September 30, 2023.

Exhibit 10.1 CVS HEALTH SEVERANCE PLAN FOR NON-STORE EMPLOYEES (Amended and Restated as of September 30, 2023) CVS HEALTH SEVERANCE PLAN FOR NON-STORE EMPLOYEES (Amended and Restated as of September 30, 2023) WHEREAS, CVS Health Corporation (the “Company”) has established the CVS Health Severance Plan for Non-Store Employees (the “Plan”) to provide financial assistance to employees in non-store po

CVS Health announces CFO Shawn Guertin to take leave of absence due to family health reasons SVP of Corporate Finance Thomas F. Cowhey Appointed Interim CFO CEO of Oak Street Health Mike Pykosz Named Interim President of Health Services

Exhibit 99.1 CVS Health announces CFO Shawn Guertin to take leave of absence due to family health reasons SVP of Corporate Finance Thomas F. Cowhey Appointed Interim CFO CEO of Oak Street Health Mike Pykosz Named Interim President of Health Services WOONSOCKET, R.I., Oct. 16, 2023 — CVS Health® (NYSE: CVS) today announced several leadership updates, effective immediately: · Executive Vice Presiden

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2023 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation) (Commission

Eighty-seven (87) percent of Aetna Medicare Advantage members in 4-star plans or higher for 2024 Commitment to exceptional service for members across the nation drove a significant improvement in member experience ratings

Exhibit 99.1 Eighty-seven (87) percent of Aetna Medicare Advantage members in 4-star plans or higher for 2024 Commitment to exceptional service for members across the nation drove a significant improvement in member experience ratings WOONSOCKET, R.I., Oct. 13, 2023 — Aetna®, a CVS Health® company (NYSE: CVS), announced today that 87 percent of its Medicare Advantage (MA) members are in 2024 Medic

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2023 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation) (Commission

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2023 (September 20, 2023) CVS HEALTH CORPORATION (Exact name of registrant as specified in charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorpo

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2023 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2023 CVS HEALTH CORPORATION (Exact name of registrant as specified in charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation) (Commission File

CVS Health Launches Cordavis New business will bring high quality biosimilar products to market with goal of reducing drug spend and ensuring access to affordable medications Cordavis to launch biosimilar Hyrimoz® with Sandoz beginning in 2024 at mor

CVS Health Launches Cordavis New business will bring high quality biosimilar products to market with goal of reducing drug spend and ensuring access to affordable medications Cordavis to launch biosimilar Hyrimoz® with Sandoz beginning in 2024 at more than 80% lower list price than Humira®* WOONSOCKET, R.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2023 CVS HEALTH CORPORATION (Exact name of registrant as specified in charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation) (Commission File

The Registrant’s Amended and Restated Severance Plan for Non-Store Employees dated January 1, 2022.

Exhibit 10.2 CVS HEALTH SEVERANCE PLAN FOR NON-STORE EMPLOYEES (Amended and Restated as of January 1, 2022) Proprietary CVS HEALTH SEVERANCE PLAN FOR NON-STORE EMPLOYEES (Amended and Restated as of January 1, 2022) WHEREAS, CVS Health Corporation (the “Company”) has established the CVS Health Severance Plan for Non-Store Employees (the “Plan”) to provide financial assistance to employees in non-st

As filed with the Securities and Exchange Commission on August 2, 2023

As filed with the Securities and Exchange Commission on August 2, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-01011 CVS HEALTH

Letter from Ernst & Young LLP acknowledging awareness of the use of a report dated

Exhibit 15.1 Letter re: Unaudited Interim Financial Information August 2, 2023 To the Shareholders and the Board of Directors of CVS Health Corporation We are aware of the incorporation by reference in the Registration Statements (Form S-3ASR No. 333-272200 and Form S-8 Nos. 333-271582, 333-270936, 333-238507, 333-230035, 333-228622, 333-167746, 333-217853, 333-208805, 333-141481, 333-139470, 333-

Signify Health, Inc. 2021 Long-Term Incentive Plan, as amended.

EXHIBIT 99.1 SIGNIFY HEALTH, INC. 2021 LONG-TERM INCENTIVE PLAN (As Amended July 28, 2023) Section 1. Purpose. The purpose of the Signify Health, Inc. 2021 Long-Term Incentive Plan (as amended from time to time, the “Plan”) is to motivate and reward employees and other individuals to perform at the highest level and contribute significantly to the success of CVS Health Corporation (the “Company”),

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 CVS HEALTH CORPORA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation) (Commission F

Amendment to Registrant’s 2007 Employee Stock Purchase Plan dated May 2, 2023 (incorporated by reference to Exhibit 10.1 of Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ending June 30, 2023).

Exhibit 10.1 ESPP AMENDMENT CVS HEALTH CORPORATION INTERNATIONAL EMPLOYEE STOCK PURCHASE PLAN (SUB-PLAN OF THE CVS HEALTH CORPORATION 2007 EMPLOYEE STOCK PURCHASE PLAN) The following constitutes the provisions of the International Employee Stock Purchase Plan (herein called the “Sub-Plan”), a sub-plan of the CVS Health Corporation (the “Company”) 2007 Employee Stock Purchase Plan, as it may be ame

CVS Health reports second quarter results

Exhibit 99.1 CVS Health reports second quarter results WOONSOCKET, RHODE ISLAND, August 2, 2023 - CVS Health Corporation® (NYSE: CVS) today announced operating results for the three months ended June 30, 2023. Second quarter highlights Key financial data •Total revenues increased to $88.9 billion, up 10.3% compared to prior year •GAAP diluted EPS of $1.48 and Adjusted EPS of $2.21 Year-to-date hig

Letter of Acknowledgment from Ernst & Young LLP re: Unaudited Interim Financial Information

Exhibit 15 August 2, 2023 To the Shareholders and the Board of Directors of CVS Health Corporation We are aware of the incorporation by reference in this Registration Statement (Form S-8) pertaining to the Signify Health, Inc.

Filing Fee Table.

Exhibit 107.1 CALCULATION OF FILING FEE TABLE S-8 (Form Type) CVS Health Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.01 par value pe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2023 (July 19, 2023)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2023 (July 19, 2023) CVS HEALTH CORPORATION (Exact name of registrant as specified in charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation) (C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number: 001-01011 A. Full title of the plan a

Form of the Registrant’s 2033 Note (incorporated by reference to Exhibit 4.3 to the Registrant’s Current Report on Form 8-K filed June 2, 2023).

EX-4.3 Exhibit 4.3 UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (“DTC”) TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO., OR TO SUCH O

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2023 CVS HEALTH CORPORATI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2023 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation) (Commission Fil

Form of the Registrant’s 2053 Note (incorporated by reference to Exhibit 4.4 to the Registrant’s Current Report on Form 8-K filed June 2, 2023).

EX-4.4 Exhibit 4.4 UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (“DTC”) TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO., OR TO SUCH O

Form of the Registrant’s 2031 Note (incorporated by reference to Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed June 2, 2023).

EX-4.2 Exhibit 4.2 UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (“DTC”) TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO., OR TO SUCH O

Form of the Registrant’s 2029 Note (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed June 2, 2023).

EX-4.1 Exhibit 4.1 UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (“DTC”) TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO., OR TO SUCH O

Form of the Registrant’s 2063 Note (incorporated by reference to Exhibit 4.5 to the Registrant’s Current Report on Form 8-K filed June 2, 2023).

EX-4.5 Exhibit 4.5 UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (“DTC”) TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO., OR TO SUCH O

Underwriting Agreement dated May 30, 2023, among CVS Health Corporation and Barclays Capital Inc., BofA Securities, Inc., Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Wells Fargo Securities, LLC as representatives of the several Underwriters named in Schedule I thereto.

EX-1.1 Exhibit 1.1 EXECUTION VERSION CVS HEALTH CORPORATION $1,000,000,000 5.000% Senior Notes due 2029 $750,000,000 5.250% Senior Notes due 2031 $1,250,000,000 5.300% Senior Notes due 2033 $1,250,000,000 5.875% Senior Notes due 2053 $750,000,000 6.000% Senior Notes due 2063 Underwriting Agreement May 30, 2023 Barclays Capital Inc. BofA Securities, Inc. Goldman Sachs & Co. LLC J.P. Morgan Securiti

CALCULATION OF FILING FEE TABLE (Form Type) CVS Health Corporation (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Calculation Fee or Forward Carry Rule Amount Registered

Exhibit 107 CALCULATION OF FILING FEE TABLE 424(b)(2) (Form Type) CVS Health Corporation (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Calculation Fee or Forward Carry Rule Amount Registered Proposed Maximum Offering Price per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Debt 5.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2023 (May 30, 2023) CVS H

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2023 (May 30, 2023) CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation)

$5,000,000,000 $1,000,000,000 5.000% Senior Notes due 2029 $750,000,000 5.250% Senior Notes due 2031 $1,250,000,000 5.300% Senior Notes due 2033 $1,250,000,000 5.875% Senior Notes due 2053 $750,000,000 6.000% Senior Notes due 2063

424B2 Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-272200 PROSPECTUS SUPPLEMENT (To Prospectus Dated May 25, 2023) $5,000,000,000 $1,000,000,000 5.000% Senior Notes due 2029 $750,000,000 5.250% Senior Notes due 2031 $1,250,000,000 5.300% Senior Notes due 2033 $1,250,000,000 5.875% Senior Notes due 2053 $750,000,000 6.000% Senior Notes due 2063 This is an offering by CVS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2023 CVS HEALTH CORPORATI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2023 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation) (Commission Fil

CVS HEALTH CORPORATION Pricing Term Sheet—May 30, 2023 $1,000,000,000 5.000% Senior Notes due 2029 $750,000,000 5.250% Senior Notes due 2031 $1,250,000,000 5.300% Senior Notes due 2033 $1,250,000,000 5.875% Senior Notes due 2053 $750,000,000 6.000% S

FWP Filed pursuant to Rule 433 Free Writing Prospectus dated May 30, 2023 Registration Statement No.

Subject to Completion, dated May 30, 2023

424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-272200 This prospectus supplement relates to an effective registration statement under the Securities Act of 1933, but is not complete and may be changed. This prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any jur

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 CVS HEALTH CORPORATI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation) (Commission Fil

EXPLANATORY NOTE

Exhibit 99.1 EXPLANATORY NOTE CVS Health Corporation, together with its subsidiaries (collectively, “CVS Health” or the “Company,” “we,” “our,” “us”) is filing this Exhibit 99.1 to revise the following sections: “Item 1. Business,” “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Item 7A. Quantitative and Qualitative Disclosures About Market Risk” a

Letter of Ernst & Young LLP re: Unaudited Interim Financial Information

Exhibit 15 May 25, 2023 To the Shareholders and the Board of Directors of CVS Health Corporation We are aware of the incorporation by reference in this Registration Statement (Form S-3) of CVS Health Corporation for the offering of debt securities of our report dated May 3, 2023 relating to the unaudited condensed consolidated interim financial statements of CVS Health Corporation that is included in its Form 10-Q for the quarter ended March 31, 2023.

Statement of Eligibility of The Bank of New York Mellon Trust Company, N.A. on Form T-1 for the Senior Indenture, dated as of August 15, 2006

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) || THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A. (Exact name of trustee as specified in its charter) (Jurisdiction o

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) CVS Health Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule (1) Amount Registered (2) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price (2) Fee Rate (1) Amount

As filed with the Securities and Exchange Commission on May 25, 2023

Table of Content As filed with the Securities and Exchange Commission on May 25, 2023 Registration No.

Statement of Eligibility of The Bank of New York Mellon Trust Company, N.A. on Form T-1 for the Subordinated Indenture, dated as of May 25, 2007

EX-25.2 6 ss2096393ex2502.htm STATEMENT OF ELIGIBILITY UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) || THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A. (Exact name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2023 (May 18, 2023) CVS H

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2023 (May 18, 2023) CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation)

By EDGAR

By EDGAR May 15, 2023 Linda Cvrkel and Suying Li United States Securities and Exchange Commission Division of Corporation Finance Office of Trade and Services 100 F Street, NE Washington, D.

LETTER

United States securities and exchange commission logo May 15, 2023 Shawn M. Guertin Executive Vice President and Chief Financial Officer CVS Health Corporation One CVS Drive Woonsocket, Rhode Island 02895 Re: CVS Health Corp Form 10-K for the Fiscal Year Ended December 31, 2022 Filed February 8, 2023 File No. 001-01011 Dear Shawn M. Guertin: We have completed our review of your filing. We remind y

LETTER

United States securities and exchange commission logo May 11, 2023 Shawn M. Guertin Executive Vice President and Chief Financial Officer CVS Health Corporation One CVS Drive Woonsocket, Rhode Island 02895 Re: CVS Health Corp Form 10-K for the Fiscal Year Ended December 31, 2022 Filed February 8, 2023 File No. 001-01011 Dear Shawn M. Guertin: We have reviewed your filing and have the following comm

Change in Control Agreement effective as of August 11, 2022 between the Registrant and Tilak Mandadi (incorporated by reference to Exhibit 10.2 of Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ending March 31, 2023).

Exhibit 10.2 CVS HEALTH CORPORATION Change in Control Agreement for Tilak Mandadi CONFIDENTIAL Revised 2020 Page 1. Definitions................................................................................................................................. 1 2. Term of Agreement..................................................................................................................... 4 3

CVS HEALTH REPORTS FIRST QUARTER RESULTS, COMPLETES ACQUISITIONS OF SIGNIFY HEALTH AND OAK STREET HEALTH

Exhibit 99.1 CVS HEALTH REPORTS FIRST QUARTER RESULTS, COMPLETES ACQUISITIONS OF SIGNIFY HEALTH AND OAK STREET HEALTH WOONSOCKET, RHODE ISLAND, May 3, 2023 - CVS Health Corporation (NYSE: CVS) today announced operating results for the three months ended March 31, 2023. FIRST QUARTER HIGHLIGHTS KEY FINANCIAL DATA •Total revenues increased to $85.3 billion, up 11.0% compared to prior year •GAAP dilu

Change in Control Agreement effective as of January 27, 2023 between the Registrant and Prem Shah (incorporated by reference to Exhibit 10.4 of Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ending March 31, 2023).

Exhibit 10.4 CVS HEALTH CORPORATION Change in Control Agreement for Prem Shah CONFIDENTIAL Revised 2020 Page 1. Definitions................................................................................................................................... 1 2. Term of Agreement..................................................................................................................... 4 3.

Restrictive Covenant Agreement dated June 20, 2022 between the Registrant and Tilak Mandadi (incorporated by reference to Exhibit 10.1 of Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ending March 31, 2023).

Exhibit 10.1 CVS Pharmacy, Inc. Restrictive Covenant Agreement I, Tilak Mandadi , enter into this Restrictive Covenant Agreement (“Agreement”) with CVS Pharmacy, Inc., on its own behalf and on behalf of its subsidiaries and affiliates (“CVS”), which is effective as of the date I sign the Agreement (“Effective Date”). 1.Consideration for Agreement. In connection with my duties and responsibilities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-01011 CVS HEALT

United States Securities and Exchange Commission Washington, D.C. 20549 Notice of Exempt Solicitation Pursuant to Rule 14a-103 Name of the Registrant: CVS Health Corporation Name of persons relying on exemption: Trillium Asset Management, LLC Address

United States Securities and Exchange Commission Washington, D.C. 20549 Notice of Exempt Solicitation Pursuant to Rule 14a-103 Name of the Registrant: CVS Health Corporation Name of persons relying on exemption: Trillium Asset Management, LLC Address of persons relying on exemption: Two Financial Center, 60 South Street, Suite 1100, Boston, MA 02111 The attached written materials are submitted pur

Restrictive Covenant Agreement dated May 11, 2022 between the Registrant and Prem Shah (incorporated by reference to Exhibit 10.3 of Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ending March 31, 2023).

Exhibit 10.3 CVS Pharmacy, Inc. Restrictive Covenant Agreement I, PREM SHAH enter into this Restrictive Covenant Agreement ("'Agreement") with CVS Pharmacy, Inc., on its own behalf and on behalf of its subsidiaries and affiliates ("CVS"), which is effective as of the date I sign the Agreement ("Effective Date"). 1.Consideration for Agreement. In connection with my duties and responsibilities at CV

Second Amendment to Five Year Credit Agreement dated as of March 23, 2023, to the Five Year Credit Agreement, dated as of May 16, 2019, as amended by the First Amendment to Five Year Credit Agreement, dated as of May 16, 2022, by and among the Registrant, the lenders party thereto and Bank of America N.A. as Administrative Agent (incorporated by reference to Exhibit 10.5 of Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ending March 31, 2023).

Exhibit 10.5 Execution Version SECOND AMENDMENT TO FIVE YEAR CREDIT AGREEMENT SECOND AMENDMENT TO FIVE YEAR CREDIT AGREEMENT (this “Amendment”), dated as of March 23, 2023, is entered into among CVS Health Corporation, a Delaware corporation (the “Borrower”), the Lenders party hereto and Bank of America, N.A., as Administrative Agent. Except as otherwise provided herein, capitalized terms used her

First Amendment to Five Year Credit Agreement dated as of March 23, 2023, to the Five Year Credit Agreement, dated as of May 16, 2022, by and among the Registrant, the lenders party thereto and Bank of America N.A. as Administrative Agent (incorporated by reference to Exhibit 10.7 of Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ending March 31, 2023).

Exhibit 10.7 Execution Version FIRST AMENDMENT TO FIVE YEAR CREDIT AGREEMENT FIRST AMENDMENT TO FIVE YEAR CREDIT AGREEMENT (this “Amendment”), dated as of March 23, 2023, is entered into among CVS Health Corporation, a Delaware corporation (the “Borrower”), the Lenders party hereto and Bank of America, N.A., as Administrative Agent. Except as otherwise provided herein, capitalized terms used herei

Second Amendment to Five Year Credit Agreement dated as of March 23, 2023, to the Five Year Credit Agreement, dated as of May 11, 2021, as amended by the First Amendment to Five Year Credit Agreement, dated as of May 16, 2022, by and among the Registrant, the lenders party thereto and Bank of America N.A. as Administrative Agent (incorporated by reference to Exhibit 10.6 of Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ending March 31, 2023).

Exhibit 10.6 Execution Version SECOND AMENDMENT TO FIVE YEAR CREDIT AGREEMENT SECOND AMENDMENT TO FIVE YEAR CREDIT AGREEMENT (this “Amendment”), dated as of March 23, 2023, is entered into among CVS Health Corporation, a Delaware corporation (the “Borrower”), the Lenders party hereto and Bank of America, N.A., as Administrative Agent. Except as otherwise provided herein, capitalized terms used her

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 CVS HEALTH CORPORATIO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation) (Commission File

Letter from Ernst & Young LLP acknowledging awareness of the use of a report dated

Exhibit 15.1 Letter re: Unaudited Interim Financial Information May 3, 2023 To the Shareholders and the Board of Directors of CVS Health Corporation We are aware of the incorporation by reference in the Registration Statements (Form S-3ASR No. 333-238506 and Form S-8 Nos. 333-271582, 333-270936, 333-238507, 333-230035, 333-228622, 333-167746, 333-217853, 333-208805, 333-141481, 333-139470, 333-636

Oak Street Health, Inc. Omnibus Incentive Plan.

EXHIBIT 99.1 OAK STREET HEALTH, INC. OMNIBUS INCENTIVE PLAN Article I PURPOSE; EFFECTIVE DATE; TERM 1.1 Purpose. The purpose of this Oak Street Health, Inc. Omnibus Incentive Plan is to enhance the profitability and value of the Company for the benefit of its Stockholders by enabling the Company to offer Eligible Individuals stock- and cash-based incentives in order to attract, retain, and reward

Filing Fee Table.

Exhibit 107.1 CALCULATION OF FILING FEE TABLE S-8 (Form Type) CVS Health Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.01 par value pe

Term Loan Agreement, dated as of May 1, 2023, by and among CVS Health Corporation, the lenders party thereto and Barclays Bank PLC, as administrative agent.

Exhibit 10.1 364-DAY TERM LOAN AGREEMENT dated as of May 1, 2023 by and among CVS HEALTH CORPORATION the Lenders Party Hereto BANK OF AMERICA, N.A., GOLDMAN SACHS BANK USA, JPMORGAN CHASE BANK, N.A. AND WELLS FARGO BANK, NATIONAL ASSOCIATION as Co-Syndication Agents and BARCLAYS BANK PLC, as Administrative Agent BARCLAYS BANK PLC, BOFA SECURITIES, INC., GOLDMAN SACHS BANK USA, JPMORGAN CHASE BANK,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2023 (May 1, 2023) CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-01011 05-0494040 (State or other jurisdiction of incorporation) (C

As filed with the Securities and Exchange Commission on May 2, 2023

As filed with the Securities and Exchange Commission on May 2, 2023 Registration No.

CVS Health completes acquisition of Oak Street Health

Exhibit 99.1 Press Release CVS Health completes acquisition of Oak Street Health WOONSOCKET, R.I., May 2, 2023 — CVS Health® (NYSE: CVS) today announced it has completed its acquisition of Oak Street Health. The acquisition will broaden CVS Health’s value-based primary care platform and significantly benefit patients’ long-term health by improving outcomes and reducing costs – particularly for tho

NOTICE OF EXEMPT SOLICITATION

NOTICE OF EXEMPT SOLICITATION Name of the registrant: CVS Health Corporation Name of person relying on exemption: New York State Comptroller Thomas P.

ARS

2022 Annual Report Making healthier happen. CVS Health One CVS Drive, Woonsocket, RI 02895 (401) 765-1500 cvshealth.com CVS Health | 2022 Annual Report 10% PCWOfficer, Director and Stockholder Information Officers Fernando Aguirre (1) (5) (6) Former Chairman and Chief Executive Officer, Chiquita Brands International, Inc. Jeffrey R. Balser, M.D., Ph.D. (4) President and Chief Executive Officer, Va

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin